REG - Poolbeg Pharma PLC - POLB 001 Data Presented at ASH

Poolbeg PharmaAnnouncement

11/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231211:nRSK2432Wa&default-theme=true

RNS Number : 2432W  Poolbeg Pharma PLC  11 December 2023

Poolbeg Pharma plc

 

POLB 001 Data Presented at ASH

POLB 001 - targeting Cytokine Release Syndrome (CRS) associated with cancer
immunotherapies

 

11 December 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company
focussed on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need and with a lack of treatment
alternatives, announces key insights from its poster presentation at the
prestigious, 65th American Society of Hematology ('ASH') Annual Meeting and
Exposition, San Diego.

 

The poster, which details POLB 001 as a potential therapy for Cytokine Release
Syndrome ('CRS') associated with cancer immunotherapies, was presented by Dr
Emma Searle from The Christie Hospital, Manchester, UK on Saturday 9 December.

 

CRS is a well-recognised toxicity that occurs frequently following certain
cancer treatments such as T-cell engaging antibodies and CAR T cell therapies.
In addition to patient mortality and morbidity risk, the high frequency of CRS
associated with these treatments represents a barrier to outpatient delivery.
The need for in-patient management of CRS adds to the overall healthcare costs
of delivering these treatments and contributes to restricting their
availability.

 

Meanwhile, the POLB 001 LPS human challenge trial conducted by Poolbeg
demonstrated good safety and tolerability, a clear dose-response relationship,
inhibition of p38 MAPK activation, and a reduction in all measured
pro-inflammatory cytokines. The effects observed were a negation of immune
over-reaction rather than an ablation of core immune function. Phase II trial
enabling activities are underway with strong interest from potential pharma
partners.

 

David Allmond, Chief Business Officer of Poolbeg Pharma, commented: "The field
of cancer immunotherapies, including CAR T and bispecific antibodies, is
burgeoning and expected to grow to over $100bn by 2030. However, CRS is rate
limiting in the delivery of these potentially lifesaving therapies. There is
strong interest from pharma partners seeking an effective and convenient
(orally administrable) solution to CRS to broaden the utilisation of their
breakthrough immunotherapies. Presenting at ASH is strong validation of POLB
001's potential and we are delighted to have the opportunity to continue our
productive partnering discussions at this prestigious conference."

 

- Ends -

 

Enquiries

 

 Poolbeg Pharma Plc                                                      +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)        +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                    +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                                 +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 

About Poolbeg Pharma

Poolbeg Pharma plc is committed to the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need. Its
model focusses upon developing its exciting clinical assets and
commercialising approved and marketed drugs to fund the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc leadership team,
with the intention of repeating Amryt's success and generating near term
revenues.

Poolbeg's clinical programmes target large addressable markets including CRS
induced by cancer immunotherapies, infectious disease, and metabolic
conditions such as obesity with the development of an oral GLP-1R agonist. It
uses a cost-effective development philosophy to generate high quality human
data to support partnering and further development. Its AI-led infectious
disease programmes analyse unique data from human challenge trials to identify
clinically relevant drug targets and treatments, leading to faster development
and greater commercial appeal.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

About ASH

 

The ASH Annual Meeting and Exposition is recognised as the world's premier
conference focussing on haematological malignancies (blood cancers) and brings
together over 25,000 industry and academic attendees each year to share the
latest scientific discoveries and advances in clinical care.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPGWPPUPWGMR